US OptionsDetailed Quotes
EBS250411C1000
- 3.23
- 0.000.00%
15min DelayClose Apr 11 16:00 ET
0.00High0.00Low
0.00Open3.23Pre Close0 Volume15 Open Interest1.00Strike Price0.00Turnover0.00%IV-8.44%PremiumApr 11, 2025Expiry Date3.62Intrinsic Value100Multiplier-4DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma1.43Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Emergent BioSolutions Stock Discussion
1. NFA (Not Financial Advice!) This is NOT a BUY or SELL advice.
2. Do NOT open position WITHOUT chart confirmation, indicators, momentum.
3. Scale out and secure profits.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 COH (cash on hand); AH (after hours): RTH (regular trading hours); PR (press release; FCF (free cash flow)
7. NEVER be a blind follower.
LASTLY, If yo...
Emergent BioSolutions Announces Stock Repurchase Program
Monday, 31st March at 8:00 am
GAITHERSBURG, Md., March 31, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced that its Board of Directors has authorized the repurchase of up to $50 million of the company's common stock on or before March 27, 2026.
"As Emergent continues the turnaround phase of our multi-year transformation plan, we expect our investment priorities to remain f...
Emergent BioSolutions Inc - Authorizes $50 Million Stock Repurchase Program
Hikma announces Health Canada approval of KLOXXADO® (naloxone HCl) Nasal Spray 8 mg
Thursday, 20th March at 8:06 am
LONDON and GAITHERSBURG, Md., March 20, 2025 (GLOBE NEWSWIRE) -- Hikma Pharmaceuticals PLC (Hikma, Group), the multinational generic pharmaceutical company, announces the approval of KLOXXADO® (naloxone HCl) Nasal Spray 8 mg, by Health Canada for the treatment of known or suspected opioid overdose, as manifested by respiratory and/or central ner...
Emergent BioSolutions Finalizes Sale of Baltimore-Bayview Manufacturing Site to Syngene International
Wednesday, 19th March at 4:30 pm
GAITHERSBURG, Md., March 19, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced that it has completed the sale of its Baltimore-Bayview drug substance manufacturing facility to Syngene International. Emergent received approximately $36.5 million at closing, which is subject to customary post-closing...
Emergent BioSolutions Announces Approximately $27 Million in Incremental Sales to Supply International Customers With Five Critical Medical Countermeasure Products
to Expanding Access to NARCAN® Nasal Spray by Supporting Organizations with New Opioid Overdose Preparedness Programs
Thursday, 13th March at 8:29 am
NYC Building & Construction Industry Safety Fund program will equip local workers, contractors and staff with NARCAN® Nasal Spray and provide trainings on how to administer the life-saving medicine
Leading mental health and addiction treatment services provider, Pathway Healthcare, breaks down stigma and access ...
2 MINUTES AGO, 8:29 AM EDT
VIA GLOBENEWSWIRE
NYC Building & Construction Industry Safety Fund program will equip local workers, contractors and staff with NARCAN® Nasal Spray and provide trainings on how to administer the life-saving medicine
Leading mental health and addiction treatment services p...
No comment yet